Akylox Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Seed

  • Investors
  • 3

Akylox General Information

Description

Developer of oral inhibitors designed to combine multiple pharmacologies in a single drug. The company's technology develops third-generation inhibitors that target wild-type and mutated tumors while sparing other tissues, enabling oncology patients to receive treatments with anti-tumor efficacy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C/O Symbion Frederiksberg
  • Nordre Fasanvej 215
  • 2000 Frederiksberg
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • C/O Symbion Frederiksberg
  • Nordre Fasanvej 215
  • 2000 Frederiksberg
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akylox Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round 01-Sep-2026 Completed Startup
3. Seed Round 01-Jan-2024 Completed Startup
2. Accelerator/Incubator 01-Jan-2024 Completed Startup
1. University Spin-Out 01-Jan-2024 Completed Startup
To view Akylox’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Akylox Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akylox Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Novo Holdings Venture Capital Minority
Innovation Office (Accelerator/Incubator) Accelerator/Incubator
University of Basel University
To view Akylox’s complete investors history, request access »

Ready to get started?

Request a free trial

Akylox FAQs

  • When was Akylox founded?

    Akylox was founded in 2024.

  • Where is Akylox headquartered?

    Akylox is headquartered in Frederiksberg, Denmark.

  • What is the size of Akylox?

    Akylox has 4 total employees.

  • What industry is Akylox in?

    Akylox’s primary industry is Drug Discovery.

  • Is Akylox a private or public company?

    Akylox is a Private company.

  • What is Akylox’s current revenue?

    The current revenue for Akylox is .

  • Who are Akylox’s investors?

    Novo Holdings, Innovation Office (Accelerator/Incubator), and University of Basel have invested in Akylox.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process